Skip Navigation

Alvogen and Yas Holding announce license and distribution agreement to commercialize generics portfolio in MENA Region

25 November 2019

Alvogen and Yas Holding have entered into a binding agreement for the exclusive partnership and distribution to commercialize Alvogen’s targeted generic pharmaceuticals portfolio in the MENA region. The portfolio consists of 28 generic pharmaceuticals in the field of oncology, autoimmune and inflammation and blood diseases that will be brought to market from 2020 and onwards.

Faysal Kalmoua, Executive Vice President of Alvogen Business Development, commented: "I am pleased to partner with Yas Holding to further expand our geographical reach into the MENA region. Yas holding is the ideal partner for us to continue our expansion with and represents another milestone in our growing commercial operations. We are also very excited to continue delivering access for patients globally, with this latest agreement allowing us to deliver high quality medicines to the MENA region.”

Alvogen’s portfolio will be commercialized in the MENA region, including Gulf, KSA, Levant, North Africa and Sub-Saharan Africa.

Ashraf Radwan, CEO Healthcare Division, YAS Holding LLC, added: “I am confident that our strategic partnership with Alvogen, for distribution and commercialization of high-value specialty care generics, will improve health outcomes and quality of life for patients in need across the MENA region. This partnership complements our existing and planned expansion in the MENA health sector, and we look forward to a successful partnership with Alvogen.

About Yas Holding Yas Holding is a business development and investment company based in Abu Dhabi in the United Arab Emirates. Active in sectors as diverse as technology, agriculture, healthcare, education and aviation, their breadth of scope is underpinned and strengthened by their commitment to the provision of high value, high quality products and services.

Yas Holding is an agile investment group with a steadfast commitment to partnership and business excellence, with a driving mission to invest in people, technology and diverse industries, to create value for their shareholders and their customers.